See more : Herborium Group, Inc. (HBRM) Income Statement Analysis – Financial Results
Complete financial analysis of Regnum Corp. (RGMP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Regnum Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- DTCOM – Direct to Company S.A. (DTCY3.SA) Income Statement Analysis – Financial Results
- SaverOne 2014 Ltd (SAVR.TA) Income Statement Analysis – Financial Results
- M.L.R.N Projects and Trade Ltd. (MLRN.TA) Income Statement Analysis – Financial Results
- Tecsys Inc. (TCS.TO) Income Statement Analysis – Financial Results
- “Bank “Saint-Petersburg” Public Joint-Stock Company (BSPB.ME) Income Statement Analysis – Financial Results
Regnum Corp. (RGMP)
Industry: Biotechnology
Sector: Healthcare
About Regnum Corp.
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C—C chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company is based in New York, New York. Regnum Corp. is a subsidiary of Phoenixus AG.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 9.00K | 6.30K | 21.40K | 18.10K | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 2.23K | 364.00 | 600.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 6.77K | 5.94K | 20.80K | 18.10K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 75.24% | 94.22% | 97.20% | 100.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 735.84K | 368.37K | 119.64K | 41.52K | 17.36K | 15.55K | 1.10K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -275.00 |
| SG&A | 735.84K | 368.37K | 119.64K | 41.52K | 17.36K | 15.55K | 825.00 |
| Other Expenses | 0.00 | 98.54K | 4.81K | 364.00 | 600.00 | 0.00 | 0.00 |
| Operating Expenses | 735.84K | 368.37K | 124.45K | 41.88K | 17.96K | 15.85K | 825.00 |
| Cost & Expenses | 735.84K | 368.37K | 126.67K | 41.88K | 17.96K | 15.85K | 825.00 |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 45.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 735.84K | 4.81K | 4.81K | 364.00 | 600.00 | 300.00 | 1.10K |
| EBITDA | -45.00K | -269.83K | -112.87K | -35.22K | 4.05K | 2.55K | 275.00 |
| EBITDA Ratio | 0.00% | 0.00% | -1,254.06% | -558.98% | 18.90% | 14.09% | 0.00% |
| Operating Income | -735.84K | -368.37K | -117.67K | -35.58K | 3.45K | 2.25K | -820.00 |
| Operating Income Ratio | 0.00% | 0.00% | -1,307.48% | -564.76% | 16.10% | 12.43% | 0.00% |
| Total Other Income/Expenses | -45.00K | 98.54K | 0.00 | 0.00 | 0.00 | 0.00 | -5.00 |
| Income Before Tax | -780.84K | -269.83K | -117.67K | -35.58K | 3.45K | 2.25K | -825.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | -1,307.48% | -564.76% | 16.10% | 12.43% | 0.00% |
| Income Tax Expense | 52.00 | -4.81 | -3.00 | 800.00 | 1.45K | 863.00 | -1.10K |
| Net Income | -780.89K | -269.83K | -117.67K | -36.38K | 2.00K | 1.39K | -825.00 |
| Net Income Ratio | 0.00% | 0.00% | -1,307.48% | -577.46% | 9.34% | 7.66% | 0.00% |
| EPS | -0.03 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.03 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 22.95M | 23.20M | 23.71M | 22.95M | 22.95M | 22.95M | 22.95M |
| Weighted Avg Shares Out (Dil) | 22.95M | 23.20M | 23.71M | 22.95M | 22.95M | 22.95M | 22.95M |
Source: https://incomestatements.info
Category: Stock Reports